A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use

Florence T. H. Wu a, Marianne O. Stefanini a, Feilim Mac Gabhann b, Christopher D. Kontos c, Brian H. Annex d, Aleksander S. Popel a, *

a Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA
b Department of Biomedical Engineering and Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA
c Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC, USA
d Division of Cardiovascular Medicine, Department of Medicine and Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, VA, USA

Received: June 10, 2009; Accepted: September 28, 2009

Abstract

Angiogenesis is the growth of new capillaries from pre-existent microvasculature. A wide range of pathological conditions, from atherosclerosis to cancer, can be attributed to either excessive or deficient angiogenesis. Central to the physiological regulation of angiogenesis is the vascular endothelial growth factor (VEGF) system – its ligands and receptors (VEGFRs) are thus prime molecular targets of pro-angiogenic and anti-angiogenic therapies. Of growing interest as a prognostic marker and therapeutic target in angiogenesis-dependent diseases is soluble VEGF receptor-1 (sVEGFR1, also known as sFlt-1) – a truncated version of the cell membrane-spanning VEGFR1. For instance, it is known that sVEGFR1 is involved in the endothelial dysfunction characterizing the pregnancy disorder of pre-eclampsia, and sVEGFR1’s therapeutic potential as an anti-angiogenic agent is being evaluated in pre-clinical models of cancer. This mini review begins with an examination of the protein domain structure and biomolecular interactions of sVEGFR1 in relation to the full-length VEGFR1. A synopsis of known and inferred physiological and pathological roles of sVEGFR1 is then given, with emphasis on the utility of computational systems biology models in deciphering the molecular mechanisms by which sVEGFR1’s purported biological functions occur. Finally, we present the need for a systems biology perspective in interpreting circulating VEGF and sVEGFR1 concentrations as surrogate markers of angiogenic status in angiogenesis-dependent diseases.

Keywords: angiogenesis • neovascularization • vascular endothelial growth factor (VEGF) • soluble fms-like tyrosine kinase 1 (sFlt-1) • molecular systems biology • systems pharmacology • computational modelling • multi-scale modelling

*Correspondence to: Aleksander S. POPEL, Department of Biomedical Engineering, Johns Hopkins University School of Medicine, 720 Rutland Ave., 611 Traylor Research Bldg., Baltimore, MD 21205, USA. Tel.: 410-955-6419 Fax: 410-614-8796 E-mail: apopel@jhu.edu
Introduction

Angiogenesis in physiology and pathology

Angiogenesis or neovascularization – the growth of new capillaries from pre-existing microvasculature [1] – sustains tissue growth and repair in normal adult physiology; during wound healing, ovarian and endometrial cycling, as well as muscle adaptations to exercise training [2, 3]. Angiogenesis can occur through distinct pathways: elevated microvascular shear stress triggers splitting angiogenesis, the intraluminal splitting of a microvessel longitudinally into two vessels; while tissue hypoxia stimulates sprouting angiogenesis, the abluminal budding of a new capillary sprout laterally from an existing microvessel [3, 4]. Related to this is intussusceptive angiogenesis caused by the formation of transvascular tissue pillars dividing the existing microvessel [5]. Tight regulation of the dynamic equilibrium between pro-angiogenic (angiogenic) and anti-angiogenic (angiostatic) processes is critical to health, as an imbalance in either direction contributes to a myriad of pathological conditions. Diseases characterized by excessive and abnormally coordinated angiogenesis include cancer, retinopathy, choroidal neovascularization, arthritis, atherosclerosis, psoriasis and endometriosis, whereas heart, brain and peripheral ischemia, as well as diabetes, hypertension, pre-eclampsia and nephropathy are characterized by insufficient angiogenesis [6].

Angiogenesis in current medicine

The wide range of ‘angiogenesis-dependent diseases’ offers the promise of angiogenesis as a therapeutic target. In clinical trials designed to manipulate the ‘angiogenic balance’ in vivo as a therapeutic strategy [2, 7, 8], anti-angiogenic therapy seeks to down-regulate angiogenesis stimulators and/or up-regulate angiogenesis inhibitors; while pro-angiogenic therapy aims to up-regulate angiogenesis stimulators and/or down-regulate angiogenesis inhibitors.

At the molecular level, common targets of these therapeutic angiogenesis inhibitors and stimulators are the ligands and receptors of the vascular endothelial growth factor (VEGF) system, in which the ligand VEGF transduces pro-angiogenic signals through receptor tyrosine kinases such as VEGFR2 (VEGFR-2), while the soluble receptor sVEGFR1 is inhibitory to angiogenic signalling, partially through VEGF sequestration.

In the category of anti-angiogenic therapy, a prime research focus has been on the development of angiogenesis inhibitors as anti-cancer drugs, including the FDA-approved bevacizumab (a humanized monoclonal antibody against VEGF), sorafenib and sunitinib (receptor tyrosine kinase inhibitors) [9]; many others still in clinical trials, including endostatin (a broad-spectrum endothelial cell inhibitor) [10, 11]; and recently, the gene/protein delivery of sVEGFR1 in pre-clinical studies [12–21]. Recent studies have demonstrated synergistic benefits of combining specific anti-angiogenic therapy with conventional chemotherapy (the use of cytotoxic agents in targeting proliferating tumour cells) [9, 22].

In the category of pro-angiogenic therapy, also known as therapeutic angiogenesis, almost a dozen clinical trials have been conducted for the gene and protein delivery of VEGF to treat coronary artery disease (CAD) and peripheral arterial disease (PAD), which are atherosclerotic vascular diseases that result in muscle ischemia [23, 24]. These randomized, controlled clinical trials have not been able to reproduce the efficacy consistently observed in pre-clinical animal studies [23, 24]. One proposed reason is that patients with these vascular diseases may also suffer from ligand insensitivity due to impaired receptor signalling or increased expression of antagonists (e.g. sVEGFR1), rather than simply a deficiency in angiogenic growth factor expression [23, 25]. Another proposed reason is that the pharmacokinetics of VEGF administration are not optimal for localizing pro-angiogenic responses within ischemic tissue, and that systemic elevation of angiogenic growth factors in blood may contribute to: (i) side effects such as transient tissue oedema (VEGF strongly induces vascular permeability) and (ii) the counter-effect of further promoting angiogenesis at the vasa vasorum feeding the growth of primary atherosclerotic plaques [23, 26, 27].

VEGF ligand and receptor system: where does sVEGFR1 fit?

Ligands: the human VEGF family

Human VEGF is a family of related proteins: VEGF-A, VEGF-B and PIGF (placental growth factor) primarily involved in the growth of blood vessels [28, 29]; and VEGF-C and VEGF-D primarily involved in lymphangiogenesis (growth of lymphatic vessels) [30]. VEGF is secreted in cysteine-linked dimeric form [28], primarily as anti-parallel homodimers (VEGF/VEGF) but possibly as heterodimers (e.g. PIGF/VEGF) [31].

In most adult tissues, VEGF-A (also commonly referred to as simply VEGF) is secreted primarily from mesenchymal, stromal and epithelial sources (e.g. myocytes in muscles; platelets in blood; tumour cells and stromal cells in tumours) to act on endothelial cells in a paracrine fashion [9, 32, 33]. The biological roles traditionally attributed to VEGF have thus been mostly vascular: promoting the survival, migration, and proliferation of endothelial cells and increasing vascular permeability of vessels [28, 33]. Both the sprouting and splitting modes of angiogenesis are dependent on VEGF-A [3, 4]. However, there is a growing list of non-vascular roles for VEGF (e.g. recruitment of inflammatory cells and endothelial precursor cells [33]; neuroprotection in central nervous system and retina [34]), as well as evidence for
autocrine and intracrine production and function of VEGF (e.g. in endothelial, tumour and haematopoietic stem cells [9, 35]).

Among the many splice variants of human VEGF-A (Fig. 1) are: the pro-angiogenic isoforms VEGF121, VEGF145, VEGF165, VEGF183, VEGF189 and VEGF206, and their anti-angiogenic counterparts VEGFxxxb most prevalent in non-angiogenic tissues, e.g. colon and skin [36, 37]. The VEGF-A exons conferring isoform-specific affinities with receptors and co-receptors are illustrated in Fig. 1. The relatively high endogenous expression of VEGF121 and VEGF165 have led to their testing as therapeutic agents in pro-angiogenic treatment for ischemic pathologies such as PAD and CAD [23, 24].

PlGF is also an important ligand for VEGFR1 and sVEGFR1, but not for VEGFR2 [28] (Fig. 1). The pathological disorder of pre-eclampsia sheds light on the critical interplay between PlGF and sVEGFR1. There is increasing evidence that hypoxia-induced placental production of sVEGFR1 plays a causal role in the pathogenesis of pre-eclampsia, a pregnancy disorder in which placental hypoxia and maternal endothelial dysfunction lead to multi-organ disease including hypertension and proteinuria [38–41]. In pre-eclampsia, increased circulating sVEGFR1 has been correlated with reduced free PlGF and reduced free VEGF in the blood compared to normal pregnancies [41–45].

Membrane-bound signalling receptors: VEGFRs

Full-length VEGF receptors-1, -2 and -3 (VEGFR1, VEGFR2, VEGFR3) are membrane-tethered receptor tyrosine kinases that are activated through homo/hetero-dimerization and ligand-induced trans-phosphorylation of intracellular tyrosine residues [29]. VEGFR3, as the receptor for VEGF-C and VEGF-D, largely mediates lymphangiogenic signalling [46] and will not be discussed here. VEGFR1 and VEGFR2 are expressed primarily on endothelial cells and they predominantly partake in the regulation of blood vessel angiogenesis (regulation of capillary sprouting and splitting), blood vessel maintenance, endothelial cell migration, endothelial cell proliferation, blood vessel permeability and dilation of blood vessels [28, 33]; but their expression on non-vascular cells (e.g. haematopoietic stem cells and megakaryocytes, the precursors of platelets; monocyctic and dendritic immune cells; neural cells) further supports the aforementioned non-vascular biological roles of VEGF in normal adult physiology [34].

VEGFR2 (also known as KDR in human beings and Flk-1 in mice) is considered the predominant effector of pro-angiogenic signalling in sprouting angiogenesis and endothelial cell survival [9]. VEGFR2 is specific to VEGF-A and does not bind PlGF [29] (Fig. 1).

On the other hand, VEGFR1 (also known as FLT-1 in human beings and Flt-1 in mice) binds both VEGF-A and PlGF [29] (Fig. 1), and can mediate either anti- or pro-angiogenic signalling depending on the activating ligand type [46]. VEGF-A binding to VEGFR1 is generally considered anti-angiogenic – possibly due to sequestration of VEGF-A which lowers its availability for VEGFR2 activation, although direct intracellular signal transduction has not been ruled out [31, 46–48]. In contrast, PlGF binding to VEGFR1 leads to pro-angiogenic signalling – either by direct intracellular activation of VEGFR1, by displacing VEGF-A which then binds and signals through VEGFR2, or by intracellular ‘crosstalk’ (intermolecular transphosphorylation) between the PlGF-activated VEGFR1 and VEGF-activated VEGFR2 [31, 46].

Fig. 1 Alternatively spliced mRNA isoforms of VEGF family members VEGF-A and PlGF. The exons encoding for protein domains that are generally responsible for interaction with receptors (sVEGR1, VEGFR1, VEGFR2), co-receptors (NRPs) and matrix proteins (HSPGs) are demarcated with colour-coded arrows. Once secreted into the extracellular space, the VEGF121 protein is generally considered a freely diffusible isoform, while VEGF165 and VEGF189 are sequestered in significant quantities at interstitial proteoglycans through its heparin-binding domain on exons 6 and 7 (see below). VEGF-A binding to cell surface receptors through their common exons 1–5 can lead to pro- or anti-angiogenic signal transduction depending on activated receptor type (see Fig. 3). Traditionally, VEGF-A was thought to bind NRP1 solely through exon 7 (contained in the higher molecular-weight isoforms, VEGF121); recently, NRP binding through exon 8 (contained in all VEGF-A isoforms) has also been suggested [37]. PlGF is (s)VEGFR1-specific and does not signal through VEGFR2. Similar to VEGF-A, there are freely diffusible isoforms (PlGF-1 and -3) and isoforms with a heparin-binding exon 6 that allows sequestration at interstitial matrix sites (PlGF-2 and -4). The molecular icons shown to the left of VEGF121, VEGF165, PlGF1 and PlGF2 are used in subsequent figures.
heterodimers (e.g. VEGFR1/VEGFR2) have not been experimentally quantified. A computational study – through mathematical modelling of various ligand-induced and ligand-independent VEGFR dimerization schemes – has predicted that heterodimers may constitute 10–50% of actively signalling VEGF receptor complexes [48]. Receptor heterodimers may be activated by ligand homodimers (e.g. VEGF/VEGF [49]) or heterodimers (e.g. VEGF/PIGF [31]), and may transduce completely different signals (in sign or magnitude) compared to the homodimerized forms of its constituents [48].

Non-signalling co-receptors and matrix proteins: HSPGs and NRPs

A variety of heparin-related proteins in the extracellular space have binding sites for the longer VEGF-A isoforms (VEGF121). A significant source of interstitial VEGF-binding sites are the ‘SAS (N-sulphated/acetylated/sulphated) domains’ [50] on glycosaminoglycan chains of heparan sulphate proteoglycans (HSPGs) such as perlecan, agrin and collagen XVIII [51, 52]. A comparatively less prevalent different source is the heparin-II binding domains of soluble fibronectins [53]. There are also HSPGs tethered on cell surfaces that facilitate surface VEGF-VEGFR binding and modulate the internalization rates of resultant complexes [46].

The cell-surface glycoproteins neuropilin-1 (NRP1) and neuropilin-2 (NRP2) were discovered originally as neuronal axon guidance receptors, but later found to be functionally significant in vascular formation as well [28, 54]. NRP1 directly binds VEGF165, PlGF-2 and possibly to a weaker degree, VEGF121 [55]; NRP2 additionally binds VEGF145 and VEGF-C, suggesting a functional bias for lymphangiogenesis [28, 46, 54].

NRPs are typically considered non-signalling receptors, but they serve as co-receptors for the VEGF family via complex formation with VEGFRs [46]. The presence of NRP1 exerts an overall pro-angiogenic effect on VEGF-signalling through two synergistic mechanisms [56]. Firstly, NRP1 can couple with VEGFR1 directly, with the resultant unligated complex NRP1-VEGFR1 permissive to subsequent binding by VEGF121 but not VEGF165 [56]. In other words, NRP1 makes VEGFR1 less available for VEGF165 activation, thereby decreasing inhibitory or modulatory VEGFR1 signalling through the VEGF165 isoform [56]. Secondly, NRP1 cannot couple VEGFR2 directly, but can still form a VEGF2-VEGFR1-NRP1 complex through non-overlapping VEGFR2-binding and NRP1-binding sites on the VEGF165 ‘bridge’ [56]. In this manner, NRP1 augments VEGF165 activation of VEGFR2 by both stabilizing VEGF165-VEGFR2 complexes and presenting NRP1-bound VEGF165 to VEGFR2, thus increasing pro-angiogenic VEGFR2 signalling through the VEGF165 isoform [56, 57]. An illustration and detailed discussion can be found in Mac Gabhann et al. [56].

Soluble receptors

Soluble VEGF receptor-1 (sVEGFR1) was initially cloned in 1993 [58] and is a truncated ~110 kDa splice variant of the 180 kDa membrane-spanning VEGFR1 [28, 45, 59]. The natural occurrence of sVEGFR1 – derived predominantly from alternative splicing [58], but possibly also from proteolytic cleavage of full-length VEGFR1 [16] – has been well documented, first in the pathophysiology of pre-eclampsia, and more recently also in numerous other physiological conditions [40, 41]. The molecular mechanisms of sVEGFR1’s purported anti-angiogenic effects have not been well elucidated, but are believed to include: (1) sequestration of VEGF ligands, much like VEGFR1 does, and effectively reducing VEGF-mediated activation of pro-angiogenic receptors and (2) heterodimerization with full-length VEGFR monomers to render the receptor dimer inactive, because sVEGFR1 lacks the intracellular tyrosine kinase domain needed to transphosphorylate its full-length partner [45, 60]. As discussed in detail below, there is growing interest in biomedical research to explore sVEGFR1 as a disease marker [42, 61–63] and a therapeutic vector for angiogenesis inhibition [12, 18, 64].

There is emerging evidence for soluble forms of other receptors as well. Soluble VEGFR2 is present in significant quantities in healthy human plasma (7–8 ng/ml) [65] and is up-regulated in acute myeloid leukaemia [66]. Soluble NRP1, a VEGF165-specific antagonist, has been documented in the kidney in human beings [67, 68]. However, this mini review will focus on sVEGFR1.

Molecular biology of sVEGFR1

The molecular weight of sVEGFR1 appears to be both glycosylation- and species-dependent. The size of sVEGFR1 has been documented as 60 kDa in mice [69], 85–90 kDa when recombinantly expressed in transfected insect cells (S9) [58], 110 kDa when expressed by human umbilical vein endothelial cells (HUVEC) and primary human dermal microvascular endothelial cells (MVEC) [59, 60], 120–130 kDa when produced by melanoma cells (COLO-800) [59], 116 kDa in human placental tissue lysates [45] and 150 kDa (that deglycosylates to 115 kDa) in serum and amniotic fluid samples from pregnant women [70]. Of note, however, it is possible that these marked differences in molecular weight, particularly in vivo, may reflect proteolytic processing of either full-length VEGFR1 or sVEGFR1 (described further below), as there is no detectable difference in molecular weight when either mouse or human sVEGFR1 cDNA is expressed in various mammalian cells (CDK, BHA, unpublished observations).

sVEGFR1 has been found to bind VEGF in monomeric, dimeric, even multimeric forms in vitro and ex vivo, forming complexes weighing 115–145 kDa [58, 59], 220–230 kDa [58, 59] and 600–700 kDa [70], respectively, which suggests ligand-induced di/multi-merization, but the relative proportions of these various forms in vivo have yet to be quantified.

While sVEGFR1 has traditionally been considered a single protein, emerging evidence point to a family of at least four alternatively spliced soluble VEGFR1 proteins [71]. The mRNA transcripts of all known sVEGFR1 variants are common through to exon 13; thus invariably, the sVEGFR1 protein retains the first six N-terminal
immunoglobulin-like (ig)-like extracellular motifs of VEGFR1, but lacks VEGFR1’s seventh Ig-like domain as well as the membrane-anchoring region, regulatory (repressive) juxtamembrane domain and intracellular signalling tyrosine kinase domains [46, 58] (Fig. 2). The four known splice variants differ in their unique C-terminus as follows: (i) sFlt1_v1, originally discovered in 1993 by Kendall et al. [58] and traditionally referred to as ‘sFlt-1’, ends with an extension of exon 13; (ii) sFlt1_v2, identified by Thomas et al. as ‘sFlt1-e15a’ in 2007 [72] and Sela et al. as ‘sFlt1–14’ in 2008 [73], includes exon 14 and terminates with exon 15a sequences [73]; (iii) sFlt1_v3, identified in 2009 by Heydarian et al. [71], includes exon 14 and terminates with exon 15b and (iv) sFlt1_v4, also identified by Heydarian et al. in 2009 [71], includes exon 14 and terminates with an extension of exon 14. A detailed illustration of the structural differences between the 3’ terminal exons of sVEGFR1 splice variants can be found in Heydarian et al. [71] Evidently, the splice variants of sVEGFR1 are subject to species-specific and cell-type-specific differential regulation at both transcriptional and translational levels, although the molecular details of which are still unclear [71, 73]. Hypoxia has been observed to up-regulate sVEGFR1 expression via HIF1-α, a process that likely contributes to the pathogenesis of pre-eclampsia [74].

Furthermore, an in vitro study documented in microvascular endothelial cells a γ-secretase-dependent intramembrane proteolysis of membrane-bound VEGFR1 and the intracellular release of an 80 kDa C-terminal fragment [16]. This finding prompted speculations of extracellular shedding of the remnant ~100 kDa N-terminal fragment, which may contribute to the interstitial/plasma population of sVEGFR1 as a proteolytically cleaved counterpart to its alternatively spliced forms. More recently, ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR1 was further documented in human leukaemia cancer cells [75]. Hereafter in this review, ‘sVEGFR1’ will refer to the entire family of alternatively spliced and cleaved variants of sVEGFR1.

Theoretically, the molecular interactions of sVEGFR1 with VEGF family ligands are expected to be similar to those of VEGFR1 due to preservation of the first six Ig-like domains: the first three domains, especially the second and third, are involved in the binding of competing ligand family members, including VEGF-A, VEGF-B and PIGF [76, 77]; the third and fourth domains are responsible for heparin-binding [77], suggesting possible sequestration at interstitial matrix sites (e.g. on heparan sulphate proteoglycans); NRP1-binding is mediated mostly through the third, but also the fourth, domain [77] and the fourth domain is responsible for ligand-induced receptor dimerization [76, 78], which presumably can facilitate both sVEGFR1-sVEGFR1 homodimerization and sVEGFR1-VEGFR heterodimerization.

**Physiological and pathophysiological roles of sVEGFR1**

Endogenous sources of sVEGFR1 in human beings include vascular endothelial cells [40], vascular smooth muscle cells [73],
activated peripheral blood mononuclear monocytes [40], placental trophoblasts [40], corneal epithelial cells [79] and proximal tubular cells of the renal epithelia [80]. As alluded to, there is evidence for cell type-specific production of sVEGFR1 splice variants: human vascular smooth muscle cells were found to express sFlt1–14 while human endothelial cells expressed the traditional sFlt-1 [73]. This wide assortment of cell types capable of sVEGFR1 expression would suggest its active involvement in multiple physiological and pathological conditions.

Several biological functions of sVEGFR1 have been deduced from its capacity to neutralize VEGF: (1) anti-angiogenesis, by dampening angiogenic VEGF-VEGFR2 signalling [12, 46]; (2) anti-oedema, by interfering with VEGF-mediated vascular permeability through VEGFR1 or VEGFR2 [46, 81] and (3) anti-inflammation, by attenuating VEGF-VEGFR1-dependent macrophage activation and migration [82]. The full extent to which the three potential actions of sVEGFR1 are involved in normal homeostasis is still uncertain. Nonetheless, exogenous administration of sVEGFR1 through gene and protein therapy has already demonstrated efficacy in controlling abnormal angiogenesis, oedema and inflammation in the 17 pre-clinical studies [12–15, 64, 81–86] summarized in Table 1.

Of the three putative functions of sVEGFR1 listed above, a great deal of in vivo evidence supports an anti-angiogenic role. In normal human physiology, sVEGFR1 was shown to be critical for the maintenance of corneal avascularity needed for optical clarity. Among many anti-angiogenic molecules (angiostatin, endostatin, etc.) present in the cornea, only sVEGFR1 was necessary to suppress the pro-angiogenic effects of local VEGF-A, at least partially through ligand trapping [69, 79]. In the setting of human disease, there is increasing evidence that the hypoxia-induced placental production of sVEGFR1 plays a causal role in the pathogenesis of pre-eclampsia. Moreover, a recent animal study suggested a possible role for sVEGFR1 in the blunted angiogenic response in ischemic skeletal muscle in diabetic PAD [25], although this association has yet to be definitively proven in human PAD. While in vivo quantification of sVEGFR1 in human studies typically has not distinguished between the splice variants of sVEGFR1, a recent study suggested that they may be responsible for distinct physiological and pathological roles in human beings, e.g. that the sFlt1–14, an isoform expressed only in primates, is thought to play an important pathogenic role in human pre-eclampsia [73].

Molecular mechanism of sVEGFR1’s anti-angiogenic potential

The precise molecular mechanisms by which sVEGFR1 exerts inhibitory effects on VEGF-dependent signalling are unclear. Nevertheless, two mechanisms have been proposed: (1) direct ligand trapping of VEGF family members (including VEGF-A and PIGF), i.e. lowering the effective concentrations of free VEGF available for receptor activation and (2) heterodimerization with surface VEGFRs to form dominant-negative complexes, i.e. lowering the effective density of unoccupied VEGFR available for ligand activation [60, 87]. More specifically, Figs 3 and 4 illustrate how the two mechanisms could affect angiogenic signalling at the endothelial cell surface and in the interstitial matrix, respectively.

In this review, we deliberate the effects of sVEGFR1 within the context of sprouting angiogenesis specifically, but because VEGF-A is also involved in the splitting mode of angiogenesis, the inhibitory effects of sVEGFR1 on capillary sprouting will likely carry over to affect splitting angiogenesis as well.

Figure 3 considers the absolute intensity of VEGF signalling at capillary surfaces – relevant for activation of angiogenic sprouting – under the ligand system of PIGF-1, PIGF-2, VEGF121 and VEGF165. In the absence of sVEGFR1, the membrane-tethered receptors (VEGFR1 and VEGFR2 homodimers; VEGFR1-VEGFR2 heterodimers) transduce ligand-specific signals, e.g. PIGF activation of VEGFR1 is pro-angiogenic while VEGF-A activation of VEGFR1 is weakly anti-angiogenic [46]. The introduction of sVEGFR1 presents new combinations of receptors that do not signal: diffusible sVEGFR1 acting as a VEGF sink (decoy receptor); and membrane-bound sVEGFR1-VEGFR heterodimers as dominant-negative complexes. Therefore, these non-signalling sVEGFR1 receptor complexes can concurrently exert anti-angiogenic effects at the cell surface by competing with the functional pro-angiogenic receptors for ligands, e.g. competing with VEGFR1 for PIGF and competing with VEGFR2 for VEGF-A (Fig 3). The intrinsic kinase and signalling activities of anti-angiogenic VEGF-VEGFR1 complexes are weaker than those of the pro-angiogenic VEGF-VEGFR2 complexes [46]; hence, the potential pro-angiogenic effects of sVEGFR1 arising from its competition with functional VEGFR1s (effectively reducing inhibitory signalling from VEGF-VEGFR1 complexes) may be much weaker than its anti-angiogenic effects described above. Also, it appears from these theoretical considerations that the extent of sVEGFR1’s anti-angiogenic effects is ligand dependent. sVEGFR1 binding to PIGF is entirely anti-angiogenic, whereas binding to VEGF-A is only partially anti-angiogenic. Ex vivo evidence (sVEGFR1 from pooled amniotic fluids) supports sVEGFR1’s capacity to act as a direct sink for VEGF and PIGF, but the relative contributions of this molecular mechanism and sVEGFR1 heterodimerization with transmembrane receptors to sVEGFR1’s observed anti-angiogenic effects in vivo [59] is not known.

Figure 4 considers how the matrix-bound VEGF in the extracellular space – which shape the interstitial VEGF gradients that guide the migration and branching of sprouting vessels [46] – may additionally be attenuated by the presence of sVEGFR1. In the absence of sVEGFR1, the VEGF gradients sensed by endothelial tip cell filopodia may comprise freely diffusing VEGF, matrix-bound VEGF and active VEGF fragments (VEGF190 and VEGF165) released from the matrix by plasmin or matrix metalloproteinase (MMP) cleavage of the larger isoforms of VEGF
| Study                  | Therapy | Vector                                      | Model                              | Disease                        | Route of administration                  | sFlt-1 expression | Effect on VEGF levels | Efficacy                                                                 |
|-----------------------|---------|---------------------------------------------|------------------------------------|---------------------------------|------------------------------------------|-------------------|-----------------------|---------------------------------------------------------------------------|
|                       |         |                                             |                                    |                                 |                                          |                   |                       | Cancer                                                                    |
|                       |         |                                             |                                    |                                 |                                          |                   |                       |                                                                            |
| Kommareddy et al. [12]| Gene (sFlt-1) | nanoparticle encapsulated plasmid DNA (non-viral) | orthotopic tumour xenograft in mice | human breast adeo-carcinoma        | intravenous (systemic); tumour-specific targeting via EPR (enhanced permeability and retention) effect | liver and tumour-specific expression; no SiM expression | N/A                    | success: suppression of tumour growth; angiostatic                        |
|                       |         |                                             |                                    |                                 |                                          |                   |                       |                                                                            |
| Kim et al. [117]      | Gene (sFlt-1) | pCMV-sFlt-1 complexed to endothelial cell-targeted polymeric gene carrier (PEI-g-PEG-RGD) | subcutaneous tumour xenograft in mice | murine colon adeo-carcinoma         | intravenous (systemic); angiogenic endothelium-targeting via integrin-binding RGD | N/A                | N/A                    | success: inhibition of tumour growth; longer survival                   |
|                       |         |                                             |                                    |                                 |                                          |                   |                       |                                                                            |
| Takei et al. [15]     | Gene (sFlt-1) | adeno-associated virus                      | subcutaneous and peritoneal tumour xenograft in mice | human ovarian serous adeo-carcinoma | intramuscular (hindlimb skeletal muscle) | high serum sFlt-1 levels; very high ascitic VEGF level | N/A                    | success: suppressed tumour growth and peritoneal dissemination; angiostatic |
|                       |         |                                             |                                    |                                 |                                          |                   |                       |                                                                            |
| Mahendra et al. [18]  | Gene (sFlt-1) | adeno-associated virus                      | subcutaneous tumour xenograft in mice | human ovarian cancer               | intramuscular (hindlimb quadriceps skeletal muscle) | systemic secretion (inferred?) and expression from muscle; no accumulation in liver | N/A                    | success: reduced tumour mass and increased tumour-free survival; no hepatotoxicity |
|                       |         |                                             |                                    |                                 |                                          |                   |                       |                                                                            |
| Mahasreshti et al. [20]| Gene (sFlt-1) | adenovirus                                 | intraperitoneal tumour xenograft in mice | human ovarian carcinoma           | intravenous (systemic)                   | ~10x higher plasma sFlt-1 levels than i.p. delivery (Mahasreshti); sFlt-1 overexpression in liver | N/A                    | failure: reduced survival duration; sFlt-1-related hepatotoxicity (hemorrhage and necrosis) |
| Mahasreshti et al. [21]| Gene (sFlt-1) | adenovirus                                 | subcutaneous tumour xenograft in mice | human ovarian carcinoma           | cancer cells infected with Ad-sFlt-1 ex vivo prior to inoculation | in situ (inferred) expression of sFlt-1 | N/A                    | success: suppressed tumour growth                                       |

Continued
| Study                  | Therapy          | Vector  | Model                          | Disease                       | Route of administration | sFlt-1 expression                   | Effect on VEGF levels | Efficacy                                      |
|------------------------|------------------|---------|--------------------------------|-------------------------------|-------------------------|-------------------------------------|----------------------|----------------------------------------------|
| Mahasreshti et al. [21]| Gene (sFlt-1)    | adenovirus | intraperitoneal tumour xenograft in mice | human ovarian carcinoma | Intraperitoneal          | no change in plasma sFlt-1 levels versus untreated (Mahasreshti) | N/A                  | success: increased survival duration          |
| Liu et al. [14]        | Gene (ECD1–3)    | adenovirus | subcutaneous tumour xenograft in mice | human multiple myeloma       | intravenous (systemic)   | 10x higher plasma sFlt-1 levels     | N/A                  | success: angiostatic suppression of tumour growth |
| Gao et al. [13]        | Gene (sFlt-1)    | adenovirus | subcutaneous tumour xenograft in mice | human tongue carcinoma       | Intratumoral            | higher serum sFlt-1                | N/A                  | success: reduced tumour growth and microvessel density |
| Zhang et al. [17]      | Gene (ECD1–3)    | adenovirus | subcutaneous tumour xenograft in mice | human colorectal cancer       | Intratumoral            | increased in tumour                | N/A                  | success: reduced tumour volume and improved survival |
| Sako et al. [83]       | Gene (sFlt-1)    | adenovirus | intraperitoneal tumour xenograft in mice | human gastric cancer         | intraperitoneal          | high in peritoneum                  | N/A                  | success: suppressed peritoneal metastasis of gastric cancer |
| Ye et al. [19]         | Cell-mediated     |          | subcutaneous (dorsal flank) tumour xenograft in mice | human follicular thyroid carcinoma | subcutaneous injection of cells on other dorsal flank | N/A                  | N/A                  | success: suppressed tumour growth and intratumoral angiogenesis |

Table 1 Continued
Table 1 Continued

| Study | Therapy | Vector | Model | Disease | Route of administration | sFlt-1 expression | Effect on VEGF levels | Efficacy |
|-------|---------|--------|-------|---------|--------------------------|------------------|----------------------|---------|
| **Ocular neovascularization** |
| Rota et al. [84] | Gene (sFlt-1) | Adenovirus | ischemia-induced retinal neovascularization in rats | ischemic retinopathy | intravitreous (intraocular) | intravitreal expression | N/A | success: inhibition of retinal neovascularization |
| Gehlbach et al. [64] | Gene (sFlt-1) | Adenovirus | laser-induced choroidal neovascularization in mice | choroidal neovascularization | intravitreous (intraocular) | higher in choroid versus retina; none in plasma (Demetriades et al.) | N/A | success: suppressed choroidal neovascularization |
| Gehlbach et al. [64] | Gene (sFlt-1) | Adenovirus | laser-induced choroidal neovascularization in mice | choroidal neovascularization | periocular | higher in choroid versus retina; none in plasma (Demetriades et al.) | N/A | success: suppressed choroidal neovascularization |
| Gehlbach et al. [64] | Gene (sFlt-1) | Adenovirus | oxygen-induced retinal neovascularization in mice | ischemic retinopathy | periocular | low in retina (higher versus un.injected); none in plasma (Demetriades et al.) | N/A | success: reduced breakdown of blood-retinal barrier (vascular permeability) but not retinal neovascularization |
| **Inflammation** |
| Afuwape et al. [85] | Gene (sFlt-1) | Adenovirus | collagen-induced arthritis in mice | rheumatoid arthritis | intravenous (systemic) | high in liver, synovial tissue and serum | reduced VEGF in ankle joint lysates | success: suppressed arthritis severity and paw swelling, likely due to reduced synovial neovascularization |
| Tsao et al. [82] | Protein (sFlt-1-Fc fusion; R&D) | N/A | induced endotoxemia and sepsis in mice | Sepsis | intraperitoneal | N/A | attenuated endotoxemia-induced increase in plasma VEGF | success: anti-inflammatory |

Continued
Table 1 Continued

| Study       | Therapy          | Vector       | Model                                | Disease                      | Route of administration | sFlt-1 expression | Effect on VEGF levels | Efficacy                                                                 |
|-------------|------------------|--------------|--------------------------------------|------------------------------|-------------------------|---------------------|-----------------------|---------------------------------------------------------------------------|
| Miotla et al. [86] | Protein (sFlt-1-PEG) | N/A          | collagen-induced arthritis in mice    | rheumatoid arthritis         | intraperitoneal         | N/A                 | N/A                   | success: reduced joint inflammation and bone/cartilage destruction        |
| Kumai et al. [81] | Gene (sFlt-1)    | adenovirus   | photochemically induced cerebral     | brain oedema (as a           | intraventricular (lateral ventricle of brain) | sFlt-1 higher in periventricular area, cerebrospinal fluid, but not in serum | No change in cerebrospinal fluid | success: reduced infarct volume, brain oedema, blood-brain barrier permeability, monocyte/macrophage infiltration; but not angiostatic in ischemic region |

Studies ordered by disease type, therapy type, then year. ‘ECD1–3’ = extracellular domains 1–3 of sFlt-1; ‘PEG’ = polyethylene glycol-linked.
The possibility that sVEGFR1 might bind to matrix-bound VEGF has not been confirmed, but theoretically sVEGFR1 could exert anti-angiogenic effects on capillary sprouts simply by masking matrix-bound VEGF from direct filopodia sensing or by protecting matrix-bound VEGF from plasmin/MMP digestion and activation [87]. In vitro evidence supports a critical role for sVEGFR1 in vessel branching [88], but it remains unclear whether this is due to sVEGFR1-mediated attenuation of interstitial gradients or sVEGFR1 heterodimerization with surface VEGFRs.

Computational simulation of these biomolecular interactions provides an important means to decipher the relative contributions of each mechanism to sVEGFR1’s anti-angiogenic effects [89, 90]. Experimentally, whether dominant-negative heterodimerization plays a significant role in vivo may be determined by quantifying the differential anti-angiogenic effects of sVEGFR1 versus ECD1–3 (the first three extracellular Ig-like domains of VEGFR1), which may not be able to dimerize with surface VEGFR, as the fourth Ig-like domain appears to play a role in receptor dimerization [76, 78]. Several studies of ECD1–3 gene delivery in vivo (Table 1) and in vitro (Table 2) have demonstrated angiostatic effects in tumour xenografts in mice as well as inhibitory effects on HUVEC proliferation, respectively. These data would suggest that VEGF sequestration alone is sufficient for sVEGFR1’s anti-angiogenic effects. However, without a quantitative, controlled comparison of sVEGFR1 versus ECD1–3 gene therapy, synergistic but redundant anti-angiogenic effects of the surface heterodimerization mechanism cannot be ruled out.

sVEGFR1 as a clinical marker for disease

Since 2000, at least 20 studies [27, 42–44, 61–63, 66, 80, 91–101] have quantified sVEGFR1 levels in a diverse range of diseases associated with pathological changes of VEGF or PlGF levels, as summarized in Tables 3 to 5. Most measurements in Tables 3–5 were of circulating (plasma/serum) sVEGFR1, but a few measurements were from urine and tissue (brain) extracts as well. Researchers are increasingly finding clinical utility for sVEGFR1 as a diagnostic (disease identification) and/or prognostic (disease progression) marker in diverse medical conditions, either independently or in combination with VEGF or PlGF (Table 3). As noted, it is well established that increased circulating sVEGFR1 and reduced free PlGF and free VEGF in the blood are correlated with the pregnancy disorder pre-eclampsia (a disease of endothelial dysfunction and impaired angiogenesis) compared to normal pregnancies [41, 44, 45]. Quantitative metrics have shown predictive value for sVEGFR1 in differentiating pre-eclampsia among suspected pregnancies [42, 43]. Conversely, among cancers (diseases of unconstrained angiogenesis), including astrocytic gliomas, primary breast cancer, pancreatic cancer and acute myeloid leukaemia, low sVEGFR1 to VEGF ratios in tumour extracts, serum or plasma correlated with higher malignancy grades of tumours, poorer patient survival or weaker responsiveness to therapy [61, 66, 91, 93]. In liver cirrhosis (an inflammatory disease of pro-angiogenic status), increases in plasma VEGF

Fig. 3 How sVEGFR1 inhibits angiogenic signalling at the cell surface: two postulated mechanisms. The full set of possible ligand-receptor complexes in the absence of sVEGFR1 is shown in the middle row; those marked with ‘+’ and ‘−’ are thought to transduce pro- and anti-angiogenic signals, respectively. The presence of sVEGFR1 allows new combinations of complexes (top and bottom rows) that do not signal (marked by ‘0’); these non-signalling species exert anti-angiogenic effects by competing for ligands with pro-angiogenic species. Specifically, in mechanism 1 (top row), sVEGFR1 homodimers (or monomers, not shown) directly compete with surface VEGFRs for ligands (e.g. VEGF and PlGF), effectively lowering free ligand concentrations available to bind unoccupied surface VEGFRs. In mechanism 2 (bottom row), sVEGFR1 monomers dimerize with surface VEGFR monomers to form dominant-negative heterodimer complexes, effectively lowering the density of functional surface VEGFRs available to bind free ligands. These two mechanisms are not mutually exclusive and both are likely to occur in vivo, although their relative propensities are not known. ‘P1’ and ‘P2’ = placental growth factors-1 and -2; ‘V_121’ and ‘V_165’ = vascular endothelial growth factor-A (VEGF) isoforms 121 and 165; ‘1’, ‘2’, ‘N’ = surface receptors VEGFR1, VEGFR2, neuropilin-1; ‘s1’ = soluble VEGFR1.
and sVEGFR1 were associated with a degree of hepatic insufficiency [62]. In suspected sepsis (systemic inflammation induced by infection), plasma sVEGFR1 and VEGF have shown potential for predicting illness severity or septic shock [63], where the changes in sVEGFR1 are thought to reflect a compensatory protective response to the VEGF-dependent inflammation [63, 102, 103]. In PAD – where skeletal muscle ischemia resulting from atherosclerotic occlusive arterial disease is accompanied by impaired arteriogenesis (the growth of arteriolar collaterals) around the primary occlusive site and impaired angiogenesis in the ischemic muscle downstream of the occlusion [23] – there is general consensus that plasma VEGF levels are increased relative to healthy controls [27, 27, 99, 101]. Although reported magnitudes of increased VEGF differ among studies, this may reflect differences in PAD severity among patient cohorts, as one study further correlated the plasma VEGF165 concentrations with PAD severity (i.e. higher in patients with critical limb ischemia than in those with intermittent claudication) [99]. However, there is contradictory evidence regarding whether plasma sVEGFR1 levels are changed in PAD patients relative to healthy controls. Blann et al. and Belgore et al. documented significantly lower levels of sVEGFR1 [27, 101], while Findley et al. and Makin et al. observed no significant differences [99, 100]. Hence the potential use of plasma sVEGFR1 as a marker for disease severity in PAD remains controversial.

Plasma VEGF and sVEGFR1: non-uniform predictors of angiogenic status across all diseases

While the studies described above have reported successful design of diagnostic/prognostic metrics for individual diseases or for severity of a given disease using combined measures of VEGF and sVEGFR1, a meta-analysis of 14 studies suggests that the plasma levels of these two angiogenic markers still do not adequately serve as reliable universal predictors of the overall angiogenic status across all angiogenesis-dependent diseases, as explained further below.

The 14 studies used in the meta-analysis (Fig. 5) included every study in Tables 3–5 that measured VEGF and/or sVEGFR1 specifically in plasma, i.e. excluding measurements from tissue homogenates, serum and urine for a consistent sampling source. The 14 studies are grouped according to disease type and angiogenic status: those marked by ‘+’ are diseases/conditions in which angiogenesis is up-regulated; ‘i’ further identifies angiogenic states that overlap with inflammatory states; those marked by ‘–’ are diseases of insufficient or impaired angiogenesis; those marked ‘±’ are atherosclerotic vascular diseases, in which angiogenesis fuels the growth of primary atherosclerotic plaques at obstructed blood vessels, but impaired angiogenesis (in addition to insufficient arteriogenesis) fails to provide sufficient oxygen delivery to the ischemic muscle tissues downstream of the obstructive site.

Firstly, plasma VEGF is elevated in almost all diseases/conditions (Fig. 5A), including the neoplastic diseases (acute myeloid leukaemia), diseases of abnormal ocular neovascularizations (retinopathy, glaucoma), inflammatory diseases (cirrhosis, sepsis) and diseases of cardiac and peripheral ischemia (CAD, PAD). Thus plasma VEGF alone cannot serve as a differential marker for angiogenic status. Secondly, there is not a consistent trend in plasma sVEGFR1 level changes within the diseases of supposedly similar angiogenic status (Fig. 5B). For example, among the diseases of aberrant ocular neovascularization, plasma sVEGFR1 decreased in the glaucomas but increased in proliferative retinopathy; among the atherosclerotic vascular diseases, plasma sVEGFR1 increased in atherosclerotic diabetes, but decreased in CAD and sometimes in PAD. Thirdly, neither can the pathological changes in plasma sVEGFR1:VEGF concentration ratios be used to differentiate between diseases of supposedly opposing angiogenic status (Fig. 5C). Thus, the simultaneous measurement of circulating VEGF and sVEGFR1 – a major VEGF neutralizing agent – in attempt to quantify the actual bioavailability of circulating VEGF, still does not uniformly predict the angiogenic status across the diseases examined here.
This section examines potential flaws and pitfalls in relying on just two markers in isolation – the plasma VEGF and sVEGFR1 levels – to encapsulate the angiogenic status of angiogenesis-dependent diseases. We also propose that a more integrative systems biology perspective [104, 105] can benefit the interpretation of these markers to aid prediction of the angiogenic status across a diversity of physiological and pathophysiological conditions.

1. **Baseline heterogeneity in clinical measurements of healthy VEGF and sVEGFR1 levels in plasma**

The quantitative variability in published measurements of circulating VEGF is well documented and can span up to three orders of magnitude due to inter-study differences in assay protocols [106, 107]. Similarly, inter-study heterogeneity in measurements of circulating sVEGFR1 was reported in a meta-analysis of 10 studies examining normal pregnancies versus pre-eclampsia [44]. Having normalized the sample sources in Fig. 5 to consider only plasma measurements, healthy VEGF levels still varied over an order of magnitude from 14.3 pg/ml to 580 pg/ml, while healthy sVEGFR1 levels varied by three orders of magnitude from 22.5 pg/ml to 28 ng/ml. This striking data variability may be attributable to inter-study methodological differences, such as in the definition of inclusion/exclusion criteria of healthy cohorts, or in the sampling, preparation and analysis of blood protein concentrations. In particular, the healthy measurements of sVEGFR1 can be divided into two extreme ranges (Fig. 5), with one set well below 2 ng/ml and the other above 15 ng/ml; it is uncertain whether the systematically higher values reported in the latter dataset [27, 95–98, 101] could be accounted for by the in-house modified ELISA protocols commonly used in those studies (Table 3). Methodological disparities aside, natural variation of the physiological baseline could account for the wide intra-study ranges observed among individuals within control groups [27, 44]. Of particular concern

| Study          | Therapy       | Vector              | Model                               | Disease                                      | Route of administration | sFlt-1 expression | Effect on VEGF levels | Efficacy                        |
|---------------|----------------|---------------------|-------------------------------------|----------------------------------------------|--------------------------|---------------------|-----------------------|--------------------------------|
| Liu et al. [14] | Gene (ECD1–3) | adenovirus          | HUVEC (endothelial cells) and KM3 (multiple myeloma cells) proliferation assay | N/A                                          | high in conditioned media from transfected KM3 cells; KM3: transfected with ADV-sFlt   | N/A                  | success: inhibited HUVEC proliferation but not KM3 proliferation |
| Gao et al. [13] | Gene (sFlt-1) | adenovirus          | HUVEC (endothelial cells) proliferation assay | N/A                                          | high in conditioned media from transfected ovarian cancer cells | N/A                  | success: inhibition of HUVEC proliferation |
| Mahendra et al. [18] | Gene (sFlt-1) | adeno-associated virus | HUVEC (endothelial cells) proliferation assay | N/A                                          | high in supernatant versus Ad-GFP          | N/A                  | success: angiostatin-comparable inhibition of HUVEC proliferation |
| Mahesreshti et al. [21] | Gene (sFlt-1) | adenovirus          | HUVEC (endothelial cells) proliferation assay | N/A                                          | high in supernatant versus mock-transduction | N/A                  | success: inhibition of HUVEC proliferation |
| Ye et al. [19] | Cell-mediated Gene (ECD1–3) | embryonic kidney cell line transduced with sFlt-1 retroviral vector | HUVEC (endothelial cells) proliferation assay | N/A                                          | dual-chamber cell coculture Transwell system | N/A                  | success: inhibition of HUVEC proliferation |

^ECD1–3’ = extracellular domains 1–3 of sFlt-1.
| Study | Author | Year | Investigated disease / condition | Sample source | Assay | Marker | Association / indication | Potential tool |
|-------|--------|------|-----------------------------------|---------------|-------|--------|--------------------------|----------------|
|       | Lamszus et al. [91] | 2003 | malignancy of astrocytic gliomas (e.g. glioblastoma = most severe grade) | homogenized tumour / brain extracts | ELISA (Bender MedSystems for sVEGFR1; R&D for VEGF) | lower sVEGFR1:VEGF | more malignant grade | Prognostic |
|       | Bando et al. [61] | 2005 | primary breast cancer | homogenized tumour extracts | ELISA (Bender MedSystems for sVEGFR1; R&D for free VEGF) | cut-off: sVEGFR1:(total VEGF) < 0.5 | poor disease-free (P = 0.008) and overall (P = 0.0002) survival | Prognostic |
|       | Clavel et al. [92] | 2007 | arthritis (progressive study) | serum | ELISA (R&D; sandwich/free for both) | serum VEGF and sFlt-1 | correlated with indices of inflammation and bone destruction | Prognostic |
|       | Chang et al. [93] | 2008 | pancreatic cancer | serum | ELISA (Quantikine, R&D; sandwich/free for both) | higher serum VEGF/sVEGFR1 | poor survival | Prognostic |
|       | Woolcock et al. [42] | 2008 | pre-eclampsia | serum | ELISA (BD) | serum cut-off: sFlt-1 > 1.9 ng/ml | pre-eclampsia with 94% sensitivity, 78% specificity, 75% positive predictive value | Diagnostic |
|       | Diab et al. [43] | 2008 | pre-eclampsia | plasma | ELISA (R&D; capture/free sVEGFR1) | plasma cut-off: sFlt-1/PlGF > 3.92 | pre-eclampsia and intrauterine growth restriction with 98% sensitivity, 95% specificity, 93% positive predictive value | Diagnostic |
|       | Widmer et al. [44] | 2007 | meta-analysis of pre-eclampsia studies (10 studies of sFlt-1; 14 studies of PlGF) | serum | ELISA (R&D; capture/free sVEGFR1) | 3rd-trimester increases in sFlt-1 and decreases in PlGF | pre-eclampsia | Diagnostic |
|       | Aref et al. [66] | 2005 | Acute myeloid leukaemia | plasma | ELISA (Quantikine, R&D) | higher plasma VEGF/sFlt-1 | poor acute myeloid leukaemia outcome (therapy response / survival) | Prognostic |
|       | Bailey et al. [94] | 2006 | acute exercise | plasma | ELISA (R&D; free VEGF) | plasma: transient peak in sVEGFR1 and later dip in VEGF | hypoxia-induction of sVEGFR1? | unknown |

Continued
| Study | Author | Year | Investigated disease / condition | Sample source | Assay | Marker | Association / indication | Potential tool |
|-------|--------|------|----------------------------------|---------------|-------|--------|--------------------------|----------------|
|       | Jaroszewicz et al. [62] | 2008 | liver cirrhosis | plasma | ELISA (Chemikine, Chemicon for free VEGF165, Quantikine, R&D for sFlt-1) | plasma VEGF and sVEGFR1 | associated with indices of hepatic insufficiency | Prognostic |
|       | Kim et al. [80] | 2005 | stages of diabetic nephropathy | plasma | ELISA (Quantikine R&D for free VEGF, ReliaTech GmbH for free sFlt-1) | increased urinary VEGF and sFlt-1 excretion | diabet ic microalbuminuria and proteinuria | unknown |
|       | Kim et al. [80] | 2005 | | urinary | ELISA (Quantikine R&D for free VEGF, ReliaTech GmbH for free sFlt-1) | | | unknown |
|       | Shapiro et al. [63] | 2008 | sepsis severity (prospective study) | plasma | ELISA (Quantikine, R&D; free VEGF and sVEGFR1) | plasma VEGF and sFlt-1 | correlated with illness severity (noninfected versus infected without shock versus septic shock) | Diagnostic (prospective) / Prognostic |
|       | Felmeden et al. [95] | 2003 | hypertension | plasma | modified ELISA (R&D) | plasma: higher VEGF, lower sFlt-1 | hypertensive (versus control) | unknown |
|       | Blann et al. [27] | 2002 | diabetes with atherosclerosis (DM+A) | plasma | modified ELISA (R&D) | plasma: higher VEGF | DM+A (versus control) | unknown |
|       | Chung et al. [96] | 2003 | CAD | plasma | modified ELISA (R&D) | plasma: higher VEGF, lower sFlt-1 | CAD (versus control) | unknown |
|       | Lip et al. [97] | 2000 | proliferative retinopathy | plasma | modified ELISA (R&D) | plasma VEGF | high in disease; low after successful laser treatment | Prognostic |
|       | Lip et al. [98] | 2002 | normal tension glaucoma (NTG) | plasma | modified ELISA (R&D) | | | unknown |
|       | Lip et al. [98] | 2002 | primary open angle glaucoma (POAG) | plasma | modified ELISA (R&D) | plasma: higher VEGF, lower sFlt-1 | glaucoma (versus control) | unknown |
|       | Findley et al. [99] | 2008 | PAD severity (intermittent claudication, IC versus critical limb ischemia, CLI) | plasma | ELISA (R&D for VEGF165 and sFlt-1) | plasma VEGF increases | correlated with PAD severity: highest in CLI versus (IC or healthy) | Prognostic |

Continued
in analysing levels of these proteins, in multiple instances the inter-study differences between ‘healthy’ baseline values often exceed in magnitude the intra-study differences between ‘healthy’ and ‘disease/condition’ values, especially for sVEGFR1 (Fig. 5). Thus, a standardization of assay protocols and calibrants for the clinical measurement of circulating VEGF and sVEGFR1 is imperative. If the variability of healthy baseline measurements does in fact reflect natural physiological variation, the significance and the diagnostic/prognostic utility of the pathological changes in plasma levels of VEGF and sVEGFR1 as shown in Fig. 5 would be questionable.

2. Effect of sVEGFR1 on VEGF bioavailability: VEGF-sVEGFR1 complexes

The rationale behind using VEGF:sVEGFR1 ratios as indicators of angiogenic status [61, 93] is based on an assumption that sVEGFR1 is the predominant regulator of circulating VEGF bioavailability, other than the intrinsic VEGF production rates. This assumption has yet to be validated, in light of mounting evidence of other potential blood carriers of VEGF: soluble VEGFR2 [65, 66], soluble NRP1 [67, 68], plasma fibronectin [53, 108–111] and platelets [112]. Furthermore, sVEGFR1 itself has additional ligand partners in addition to VEGF-A, as it also binds VEGF-B and placental growth factor (PIGF) [87, 113]. In order to assess how much of the bound/unavailable circulating VEGF is sVEGFR1-complexed and vice versa, simultaneous quantifications are necessary for free VEGF (capture/sandwich immunoassays [106]), free sVEGFR1, total VEGF (competitive immunoassays [106]), total sVEGFR1 and VEGF-sVEGFR1 complexes (e.g. the specific modified assay developed by Belgore et al. [101]). In the ‘Assay’ column in Table 3, we note where free VEGF and sVEGFR1 were measured; in other cases the authors did not specify whether the measurement was for free or total species. In future experimental studies, this distinction should be carefully addressed in the design and reporting of experimental methodology. Crucially, experiments are needed to specifically determine whether a given ELISA will distinguish between bound and unbound proteins, i.e. whether individual antibodies detect epitopes that are masked after binding. In fact, differences in ELISA specificity may account for the observed marked differences in levels of circulating VEGF and sVEGFR1. Without direct quantifications of circulating VEGF-sVEGFR1 complexes, it would be nearly impossible to decipher, for example, how much of a pathological increase in available free VEGF is due to: increased VEGF production rate, increased VEGF-sVEGFR1 complex dissociation, or altered VEGF-binding to other carrier proteins.

3. Compartmental analysis: biotransport and biodistribution

VEGF and sVEGFR1 are soluble proteins subjected to pharmacokinetic transport between organ and tissue compartments (e.g. due to vascular permeability and lymphatic drainage). As such, their plasma concentrations do not necessarily reflect their interstitial concentrations within organs/tissues where the local angiogenic status is of interest with respect to the disease under consideration. This may be the case in PAD, in which two human...
Table 4  Meta-analysis of 20 studies of human VEGF and sVEGFR1 measurements in health and disease: healthy controls

| Study                        | Year | n (# of patients) | Cohort description | VEGF | sVEGFR1 |
|------------------------------|------|-------------------|--------------------|------|---------|
| Lamszus et al. [91]          | 2003 | 5                 | Healthy white matter | 0.06 ± S.D. | 0.1 ng/mg | 0 ± S.D. | 0 ng/mg |
| Bando et al. [61]            | 2005 | N/A               | N/A                | N/A  | N/A     |
| Clavel et al. [92]           | 2007 | N/A               | N/A                | N/A  | N/A     |
| Chang et al. [93]            | 2008 | 60                | Healthy            | 187.63 ± S.D. | 393.32 pg/ml | 0.01555 ± S.D. | 0.00196 ng/ml |
| Woolcock et al. [42]         | 2008 | 18                | Normotensive women | N/A  | 0.47 IQR | 0.11–0.89 pg/ml | 0.0726 ng/ml |
| Diab et al. [43]             | 2008 | 66                | Normal pregnant women | N/A  | 0.5133 ± S.D. | 0.0726 ng/ml |
| Widmer et al. [44]           | 2007 | N/A               | N/A                | N/A  | N/A     |
| Aref et al. [66]             | 2005 | 10                | Healthy            | 138 ± S.E.M. | 4.7 pg/ml | 0.0225 ± S.E.M. | 0.0009 ng/ml |
| Bailey et al. [94]           | 2006 | 5                 | Healthy @ basal    | 37.3 ± S.E. | 7.7 pg/ml | 0.0488 ± S.E. | 0.009 ng/ml |
| Jaroszewicz et al. [62]      | 2008 | 15                | Healthy            | 46.8 ± S.E.M. | 4.1 pg/ml | 0.1051 ± S.E.M. | 0.0059 ng/ml |
| Kim et al. [80]              | 2005 | 47                | Healthy            | 14.3 IQR | 48 pg/ml | 0.11 IQR | 0.25 ng/ml |
| Kim et al. [80]              | 2005 | 47                | Healthy            | 27.8 IQR | 49 pg/mg creatinine | 0.05 IQR | 0.21 ng/mg creatinine |
| Shapiro et al. [63]          | 2008 | 66                | Noninfected        | 580 ± S.D. | 380 pg/ml | 1.59 ± S.D. | 0.79 ng/ml |
| Felmeden et al. [95]         | 2003 | 60                | Normotensive healthy | 125 IQR | 40–213 pg/ml | 17 IQR | 10–33 ng/ml |
| Blann et al. [27]            | 2002 | 14                | Healthy            | 92.5 IQR | 20–175 pg/ml | 20 IQR | 3–32 ng/ml |
| Chung et al. [96]            | 2003 | 34                | Healthy            | 80 IQR | 20–176 pg/ml | 20 IQR | 9–40 ng/ml |
| Lip et al. [97]              | 2000 | 18                | Healthy            | 50 IQR | 16–113 pg/ml | 20 IQR | 9.6–26 ng/ml |
### Table 4

| Study               | Healthy Control                        | VEGF          | sVEGFR1       |
|---------------------|----------------------------------------|---------------|---------------|
| Author              | Year                                   | n (# of patients) | Cohort description | Mean | Error | Units | Mean | Error | Units |
| Lip et al. [98]     | 2002                                   | 26            | Healthy       | 83   | IQR   | 13–125 | pg/ml | 28   | IQR   | 18–39 | ng/ml |
| Findley et al. [99] | 2008                                   | 23            | Healthy       | 50   | ± S.D. | 30     | pg/ml | 0.9  | ± S.D. | 0.4   | ng/ml |
| Makin et al. [100]  | 2003                                   | 50            | Healthy       | 78   | IQR   | 69–100 | pg/ml | 0.9  | IQR   | 0.2–2.9 | ng/ml |
| Blann et al. [27]   | 2002                                   | 70            | Healthy       | 77.5 | IQR   | 20–149 | pg/ml | 22   | IQR   | 14–37  | ng/ml |
| Belgore et al. [101]| 2001                                   | 40            | Healthy       | 113  | IQR   | 33–231 | pg/ml | 21   | IQR   | 10–78  | ng/ml |

Studies ordered by source and disease/condition, then by measured healthy values of plasma sVEGFR1. S.D. = standard deviation, S.E.M. = standard error in the mean, IQR = interquartile range.

### Table 5

| Study               | Disease/Condition                | VEGF          | sVEGFR1       |
|---------------------|----------------------------------|---------------|---------------|
| Author              | Year                             | n (# of patients) | cohort description | mean | error | units | mean | error | units |
| Lamszus et al. [91]| 2003                             | 46            | glioblastomas | 11.9 | ± S.D. | 20.74 | ng/mg protein | 3.26 | ± S.D. | 4     | ng/mg protein |
| Bando et al. [61]  | 2005                             | 202           | all primary breast cancers | 0.532 | ± S.D. | 0.432–0.632 | 32 | 4 | 95% CI | 0.849–1.048 | ng/mg protein |
| Clavel et al. [92] | 2007                             | 310           | early arthritis @ baseline | 465 | ± S.D. | 270 | pg/ml | 0.035 | ± S.D. | 0.03 | ng/ml |
| Clavel et al. [92] | 2007                             | 310           | early arthritis @ 1 yr | 1212 | ± S.D. | 1041 | pg/ml | 0.095 | ± S.D. | 0.073 | ng/ml |
| Chang et al. [93]  | 2008                             | 92            | pancreatic cancer | 538.8 | ± S.D. | 559.5 | pg/ml | 0.05094 | ± S.D. | 0.05117 | ng/ml |
| Woolcock et al. [42]| 2008                            | 18            | pre-eclampsia | N/A | 3.13 | IQR | 2.14–4.17 | ng/ml |
| Diab et al. [43]   | 2008                             | 8             | early onset pre-eclampsia | N/A | 2.562 | ± S.D. | 1.611 | ng/ml |
| Widmer et al. [44] | 2007                             |               |               |               |               |               |               |               |               |               |
| Aref et al. [66]   | 2005                             | 43            | Acute myeloid leukaemia | 373.9 | ± S.E.M. | 34 | pg/ml | 0.0497 | ± S.E.M. | 0.0028 | ng/ml |
| Bailey et al. [94] | 2006                             | 5             | healthy @ peak change | 17.5 | ± S.E. | 2.5 | pg/ml @ 2 hrs post-ex. | 0.0729 | ± S.E. | 0.0146 | ng/ml |

continued
studies have documented increased sVEGFR1 in the plasma (Fig. 5), yet in a diabetic mouse model of PAD, muscle expression of sVEGFR1 increased after surgically induced hindlimb ischemia [25]. To the best of our knowledge, there are currently no available data assessing interstitial levels of sVEGFR1 in human beings. Interstitial VEGF has been measured by microdialysis [114, 115], but technical concerns have been raised regarding the accuracy in using high molecular-weight cut-off microdialysis membranes to study macromolecules such as proteins, including unwanted ultrafiltration that could alter interstitial space compositions [116]. In the case that interstitial sVEGFR1 is truly elevated in PAD patients relative to healthy controls, in contrast to the unchanged/lowered sVEGFR1 levels observed in plasma, one explanation is that biotransport and biodistribution of sVEGFR1 are altered in PAD, e.g. lowered lymphatic drainage might lead to accumulation of sVEGFR1 within ischemic tissues.
Therefore, in diseases in which the angiogenic markers in plasma seem to predict an angiogenic status other than that expected for the disease, the disparity may be corrected by examining the actual interstitial concentrations of these markers in the diseased compartments.

4. Pathogenic phenomenon versus compensatory response

Even in the case that plasma levels of circulating VEGF and sVEGFR1 accurately reflect the interstitial levels within diseased tissues, it is difficult to discern whether static (single time-point) blood samples reflect pathogenic phenomena or compensatory responses. For instance, in the case of cancer, elevated plasma VEGF (Fig. 5) typically represents a pathogenic process in which tumour hypoxia induces increased VEGF expression, thereby stimulating excessive angiogenesis in the diseased tissue. On the other hand, in atherosclerotic vascular diseases, the elevated plasma VEGF (Fig. 5) may be a result of compensatory VEGF up-regulation in response to ineffective angiogenesis at the ischemic muscle tissues or, as in tumours, a pathogenic increase in VEGF that stimulates the growth of the atherosclerotic plaque [26]. In fact, it is known that both VEGF and (s)VEGFR1 expression are hypoxia-inducible due to the presence of a hypoxia response element (HRE) in their gene promoter regions [87]; thus it is plausible that expression of VEGF and sVEGFR1 is up-regulated in both cancer and ischemic disease. In other words, what is different between
these diseases may be in the tissue responsiveness to ligand availability – excessive in cancer and deficient in ischemic diseases, as illustrated in Fig. 6. Therefore a more complex ‘systems biology’ interpretation of the plasma levels of VEGF and sVEGFR1 (the inputs) – one that considers downstream ligand-receptor interactions and signalling cascades (represented as black boxes in Fig. 6) – would be needed to predict the angiogenic status (the output) across these different disease states.

Concluding remarks

Taken together, these necessary distinctions suggest that a systems biology model could provide important insights into the use of plasma VEGF and sVEGFR1 levels as surrogate markers of disease status for a variety of angiogenesis-dependent diseases. To generate such a mathematical model, further experimental data are needed to inform model extensions and model parameterizations: (1) standardization of methodological protocols and definition of healthy baseline ranges of circulating VEGF and sVEGFR1 under normal physiological fluctuations is needed to constrain their healthy ‘setpoints’ for model predictions; (2) quantification for the plasma concentrations and binding kinetics of all competing blood carriers, including sVEGFR1, is needed to accurately predict the bioavailability of circulating free VEGF; (3) real-time tracking of the biotransport processes (vascular permeability rates, lymphatic drainage rates, etc.) and systemic distributions (interstitial, intracellular and intravascular densities in various tissues) of VEGF and sVEGFR1 will help elucidate the relationship between protein measurements from varying body compartments; and (4) identification and model representation of all molecular components involved in the signal transduction networks of the VEGF system, including feedback loops (e.g. receptor expression levels as dependent on ligand activation and auto-phosphorylation), is crucial for discerning between pathogenic and compensatory responses in interpreting the correlation between concentrations of suspected protein markers and a particular disease status.

Acknowledgements

We thank Dr. Amina A. Qutub, David Noren, Prakash Vempati and all members of the Popel Lab for their helpful discussions. We also thank Dr. Eli Keshet and Shay Sela for useful discussion of sFlt-1. This work was supported by the NIH grants, R33 HL087351 and R01 HL079653. F.T.H.W. was supported by an NSERC PGS-M scholarship.

References

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932–6.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6: 273–86.
3. Brown MD, Hudlicka O. Modulation of physiological angiogenesis in skeletal muscle by mechanical forces: involvement of VEGF and metalloproteinases. Angiogenesis. 2003; 6: 1–14.
4. Williams JL, Weichert A, Zakrzewicz A, et al. Differential gene and protein expression in abluminal sprouting and intraluminal splitting forms of angiogenesis. Clin Sci. 2006; 110: 587–95.
5. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn. 2004; 231: 474–88.
6. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–60.
7. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438: 967–74.
8. Testa U, Pannitteri G, Condorelli GL. Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med. 2008; 9: 1190–221.
9. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358: 2039–49.
10. Verhoef C, de Wit JHW, Verheul HMW. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des. 2008; 12: 2623–30.
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249–57.
12. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sflt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 2007; 14: 488–98.
13. Gao Z, Wei Y, Yang P, et al. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Oral Oncol. 2007; 43: 477–83.
14. Liu J, Li J, Su C, et al. Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Biochim Biophys Sin. 2007; 39: 499–506.
15. Takei T, Sakai S, Ono T, et al. Fabrication of endothelialized tube in collagen gel as starting point for self-developing capillary-like network to construct three-dimensional organs in vitro. Biotechnol Bioeng. 2008; 95: 1–7.
16. Cai J, Jiang WG, Grant MB, et al. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006; 281: 3604–13.
17. Zhang Z, Zou W, Wang J, et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble flt-1. Mol Ther. 2005; 11: 553–62.
18. Mahendra G, Kumar S, Isayeva T, et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. 2005; 12: 26–34.
19. Ye C, Feng C, Wang S, et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology. 2004; 145: 817–22.
20. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res. 2003; 9: 2701–10.
21. Maharaj AS, Navarro JG, Kataram M, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res. 2001; 7: 2057–66.

22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 423–36.

23. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg. 2004; 28: 9–23.

24. Yia-Hertuaa SL, Rispens TT, Vajanto I, et al. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007; 49: 1015–26.

25. Hazarika S, Dokun AO, Li Y, et al. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007; 101: 948–56.

26. Moulton KS. Plaque angiogenesis and athrosclerosis. Curr Atheroscler Rep. 2001; 3: 225–33.

27. Blann AD, Beligore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, fIIT-1, in the plasma of patients with coronary or peripheral athrosclerosis, or type II diabetes. Clin Sci. 2002; 102: 187–94.

28. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005; 109: 227–41.

29. Zachary I. VEGF signalling: integration and molecular cross talk between the VEGF receptor-1 and -2 heterodimer. J Biol Chem. 2005; 280: 9904–12.

30. Luttun A, Carmeliet P. Soluble VEGF receptor Flt-1: the elusive preeclampsia factor discovered? J Clin Invest. 2003; 111: 600–2.

31. Diab AE, El-Behery MM, Ebrahiem MA, et al. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midterm uterine artery doppler velocimetry. Int J Gynaecol Obstet. 2008; 102: 146–51.

32. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007; 109: 168–80.

33. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004; 95: 884–91.

34. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol. 2004; 286: H153–64.
the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. 
*Biochem Biophys Res Commun.* 1996; 226: 324–8.
61. Bando H, Weich HA, Broekelmann M, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. *Br J Cancer.* 2005; 92: 533–61.
62. Jaroszewicz J, Januszkiewicz M, Flisiak R, et al. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. *Cytochrome.* 2008; 44: 14–7.
63. Shapiro NI, Yano K, Okada H, et al. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. *Shock.* 2008; 29: 452–7.
64. Gehlbach P, Demetriades AM, Yamamoto S, et al. Pericellular gene transfer of sFlt-1 suppresses ocular neo-vascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. *Hum Gene Ther.* 2003; 14: 129–41.
65. Aref S, El Sherbiny M, Goda T, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. *Mol Cancer Res.* 2004; 2: 315–26.
66. Loriguer S, Berndt S, Blacher S, et al. Implication of soluble receptors of VEGF, sVEGFR-1 and sVEGFR-2, in angiogenesis. *Am J Reprod Immunol.* 2008; 60: 85.
67. Gagnon ML, Bielenberg DR, Gechtman Z, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. *Proc Natl Acad Sci USA.* 2000; 97: 2573–8.
68. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. *Nature.* 2006; 443: 993–7.
69. Banks RE, Forbes MA, Searles J, et al. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, fit-1. *Mol Hum Reprod.* 1998; 4: 377–86.
70. Heydarian M, McCaffrey T, Florea L, et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. *Placenta.* 2009; 30: 250–5.
71. Thomas CP, Andrews NJ, Liu KZ. Intrinsic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. *FASEB J.* 2007; 21: 3885–95.
72. Sela S, Iltn A, Natanson-Yaron S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. *Circ Res.* 2008; 102: 1566–74.
73. Thomas CP, Andrews NJ, Raikwar NS, et al. A recently evolved novel trophoblast-enriched sFlt1 variant is upregulated in hypoxia and in preeclampsia. *J Clin Endocrinol Metab.* 2009.
74. Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. *Cancer Res.* 2009.
75. Barleon B, Totzke F, Herzog C, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. *J Biol Chem.* 1997; 272: 10382–5.
76. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor fit-1. *J Biol Chem.* 2000; 275: 26690–8.
77. Cebe-Suarez S, Zehnder-Fjallman A, Hummersone-Chapuis D, et al. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1 into circulating soluble form of vascular endothelial growth factor homeostasis in preeclampsia. *FASEB J.* 2007; 21: 1465–71.
78. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor fit-1. *J Biol Chem.* 2000; 275: 26690–8.
79. Cebe-Suarez S, Zehnder-Fjallman A, Hummersone-Chapuis D, et al. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1 into circulating soluble form of vascular endothelial growth factor homeostasis in preeclampsia. *FASEB J.* 2007; 21: 1465–71.
80. Hornig C, Weich HA. Soluble VEGF receptors. *Angiogenesis.* 1999; 3: 33–9.
81. Kappas NC, Zeng G, Chappell JC, et al. The VEGF receptor fit-1 spatially modulates fkl signaling and blood vessel branching. *J Cell Biol.* 2003; 167–77.
82. Chan YF, Chen C, Chan CT, et al. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. *J Exp Med.* 2003; 198: 83–91.
83. Sako A, Kitayama J, Koyama H, et al. The role of VEGF receptor flt-1 spatially modulate the vascular endothelial growth factor homeostasis in preeclampsia. *FASEB J.* 2007; 21: 1465–71.
84. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor fit-1. *J Biol Chem.* 2000; 275: 26690–8.
85. Cebe-Suarez S, Zehnder-Fjallman A, Hummersone-Chapuis D, et al. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1 into circulating soluble form of vascular endothelial growth factor homeostasis in preeclampsia. *FASEB J.* 2007; 21: 1465–71.
96. Chung NA, Lydakis C, Belgore F, et al. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003; 89: 1411–5.
7. Lip PL, Belgore F, Blann AD, et al. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci. 2000; 41: 1215–9.
98. Lip PL, Belgore F, Blann AD, et al. Plasma vascular endothelial growth factor, soluble VEGF receptor, and von willebrand factor in glaucoma. Br J Ophthalmol. 2002; 86: 1299–302.
99. Findley CM, Mitchell RG, Duscha BD, et al. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol. 2008; 52: 87–93.
100. Makin AJ, Chung NA, Silverman SH, et al. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci. 2003; 104: 397–404.
101. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci. 2001; 100: 567–75.
102. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med. 2006; 203: 1447–58.
103. Yano K, Okada Y, Beldi G, et al. Elevated levels of placent al growth factor represent an adaptive host response in sepsis. J Exp Med. 2008; 205: 2623–31.
104. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation. 2008; 15: 715–38.
105. Qutub AA, Mac Gabhann F, Karagiannis ED, et al. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag. 2009; 28: 14–31.
106. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001; 47: 617–23.
107. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007; 97: 978–85.
108. Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem. 1983; 258: 4641–7.
109. Mosher DF. Physiology of fibronectin. Annu Rev Med. 1984; 35: 561–75.
110. Taylor RN, Crombleholme WR, Friedman SA, et al. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol. 1991; 165: 895–901.
111. Mitsi M, Hong Z, Costello CE, et al. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry. 2006; 45: 10319–28.
112. Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007; 13: 5341–7.
113. Autiero M, Luttmann A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003; 1: 1356–70.
114. Gavin TP, Ruster RS, Carrithers JA, et al. No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men. J Physiol. 2007; 585: 231–9.
115. Hoffner L, Nielsen JJ, Langberg H, et al. Exercise but not prostanooids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. J Physiol. 2003; 550: 217–25.
116. Arner P. Microdialysis: use in human exercise studies. Proc Nutr Soc. 1999; 58: 913–7.
117. Kim WJ, Yokacman JW, Jeong JH, et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release. 2006; 114: 381–8.